Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.
Filipovic-Pierucci A, Durand-Zaleski I, Butel T, Greene S, Hovasse T, Iñiguez A, Nazzaro MS, Oldroyd KG, Talwar S, Richardt G, Windhovel U, Urban P, Morice MC. Filipovic-Pierucci A, et al. Among authors: hovasse t. EuroIntervention. 2018 Feb 20;13(14):1688-1695. doi: 10.4244/EIJ-D-17-00286. EuroIntervention. 2018. PMID: 28891471 Free article.
Interventions in chronic total occlusions with bifurcation lesions: incidence, treatment, and in-hospital outcome.
Konstantinidis NV, Chevalier B, Hovasse T, Garot P, Benamer H, Unterseeh T, Champagne S, Sanguineti F, Neylon A, Moysiadis T, Avran A, Louvard Y, Lefèvre T. Konstantinidis NV, et al. Among authors: hovasse t. Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):980-990. doi: 10.1016/j.rec.2023.03.023. Epub 2023 May 26. Rev Esp Cardiol (Engl Ed). 2023. PMID: 37245654 English, Spanish.
A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. Stone GW, et al. J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4. J Am Coll Cardiol. 2011. PMID: 21470815 Free article. Clinical Trial.
[Percutaneous aortic valve implantation: results and perspectives].
Hovasse T, Lefèvre T, Morice MC, Chevalier B, Hayashida K, Garot P, Romano M, Donzeau-Gouge P, Farge A, Bouvier E, Cormier B. Hovasse T, et al. Presse Med. 2011 Jul-Aug;40(7-8):732-9. doi: 10.1016/j.lpm.2011.02.037. Epub 2011 Apr 20. Presse Med. 2011. PMID: 21511426 French.
Transfemoral aortic valve implantation new criteria to predict vascular complications.
Hayashida K, Lefèvre T, Chevalier B, Hovasse T, Romano M, Garot P, Mylotte D, Uribe J, Farge A, Donzeau-Gouge P, Bouvier E, Cormier B, Morice MC. Hayashida K, et al. Among authors: hovasse t. JACC Cardiovasc Interv. 2011 Aug;4(8):851-8. doi: 10.1016/j.jcin.2011.03.019. JACC Cardiovasc Interv. 2011. PMID: 21851897 Free article.
True percutaneous approach for transfemoral aortic valve implantation using the Prostar XL device: impact of learning curve on vascular complications.
Hayashida K, Lefèvre T, Chevalier B, Hovasse T, Romano M, Garot P, Mylotte D, Uribe J, Farge A, Donzeau-Gouge P, Bouvier E, Cormier B, Morice MC. Hayashida K, et al. Among authors: hovasse t. JACC Cardiovasc Interv. 2012 Feb;5(2):207-14. doi: 10.1016/j.jcin.2011.09.020. JACC Cardiovasc Interv. 2012. PMID: 22361606 Free article.
150 results